REGENTIS BIOMATERIALS LTD. (RGNT) Form 6-K — Jul 15, 2026
Regentis Biomaterials received European Notified Body approval for its next-generation solvent-free manufacturing process for GelrinC, increasing production yield by approximately 400% and lowering manufacturing costs. The approval clears the way for the commercial launch of the cell-free hydrogel implant in Europe, enabling scalable production to support the company's expanding network of European Centers of Excellence. GelrinC addresses a $3 billion market in the U.S.
Key figures
- Annual Cases Us
- 470,000
- Market Size Usd
- $3 billion
- Yield Increase
- 400%
- Fda Study Enrollment
- >50%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.